Apomorphine

Active ingredient description

Apomorphine is a direct stimulant of dopamine receptors and while possessing both D1 and D₂ receptor agonist properties does not share transport or metabolic pathways with levodopa. Its actions on parkinsonian motor disability are likely to be mediated at post-synaptic receptor sites.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

G04BE07

Apomorphine

G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BE Drugs used in erectile dysfunction

Discover more medicines within G04BE07

N04BC07

Apomorphine

N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BC Dopamine agonists

Discover more medicines within N04BC07

Medicines

Apomorphine is the active ingredient of these drugs:

APO-GO

Austria Cyprus Estonia Finland Ireland

APOKINON

France Tunisia

APOKYN

United States

APOMINE

Australia

BRITAJECT

Lithuania

DACEPTON

Austria Estonia Finland Ireland Lithuania

DOPACEPTIN

France

KYNMOBI

Canada United States

MOVAPO

Australia Canada New Zealand

UPRIMA

South Africa

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

KYNMOBI Sublingual film

Structured Product Labeling (SPL/PLR)

APO-GO Solution for injection

Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 267.322 g/mol

3D molecular structure

3D representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 41372-20-7
CAS Substance: 58-00-4
DrugBank Drug: DB00714
KEGG Drug: D02004
RxNorm Ingredient: 1043
SNOMED-CT Concept: 387375001: Apomorphine (substance)
UNII Identifier: N21FAR7B4S: APOMORPHINE

Next: Usage >